NeuraMetrix, Inc.

07/18/2025

Brain Monitoring Market is estimated to be valued at USD 4,154.7 Mn in 2025 and is expected to reach USD 6,715.3 Mn by 2032, growing at a compound annual growth rate (CAGR) of 7.1% from 2025 to 2032. By OpenPR [Press-release] https://www.openpr.com/news/4106078/brain-monitoring-market-exclusive-report-with-detailed-study

Brain Monitoring Market is estimated to be valued at USD 4 154 7 Mn in 2025 and is expected to reach USD 6 715 3 Mn by 2032 growing at a compound annual growth rate CAGR of 7 1 from ...

06/11/2025

All Health Tech highlighted on World Brain Tumour Day (June 8) the importance of early diagnosis of brain diseases and new technologies that can facilitate early detection. One of the technologies listed is NeuraMetrix, Inc., a digital brain biomarker that detects changes in typing patterns indicative of neurological issues.

🧠 𝐉𝐮𝐧𝐞 8 𝐢𝐬 𝐖𝐨𝐫𝐥𝐝 𝐁𝐫𝐚𝐢𝐧 𝐓𝐮𝐦𝐨𝐮𝐫 𝐃𝐚𝐲 A day to raise awareness, honour the fighters, and fuel the future of brain health innovation. Brain tumours, though rare, can be devastating. Even benign ones can disrupt memory, speech,...

02/22/2025

Key Players in the Digital Neuro Biomarkers Market include NeuraMetrix, Inc. with its typing cadence SaMD.

According to a new research report by SNS Insider, the Digital Neuro Biomarkers Market was valued at USD 538.96 million in 2023 and is projected to reach USD 4592.14 million by 2032. Via EIN Presswire

https://www.einnews.com/pr_news/788038965/digital-neuro-biomarkers-market-to-reach-usd-4592-14-million-by-2032-sns-insider

Rising Neurological Disorders and Technological Innovations Drive Market Growth at 25.96% CAGR

02/22/2025

According to Nova One Advisor, the global neurological biomarkers market size was estimated at USD 9.45 billion in 2024 and is expected to hit around USD 31.82 billion by 2034. Via BioSpace https://www.biospace.com/press-releases/neurological-biomarkers-market-size-to-hit-usd-31-82-billion-by-2034

02/17/2025

A recent report in the journal Nature Medicine projects a 42% lifetime risk for dementia in the US by the year 2060, which is approximately twice the current level. Currently, about 500,000 cases of dementia are diagnosed annually, and they project that by the year 2060, about 1 million cases per year will be diagnosed. By Dr JoAnn Manson, professor of medicine at Harvard Medical School and Brigham and Women's Hospital via Medscape

https://www.medscape.com/viewarticle/our-looming-high-dementia-burden-can-it-be-averted-2025a10001fb

Dr JoAnn Manson discusses the urgent need to implement what we already know about preventing dementia.

01/15/2025

The Digital Neuro Biomarkers Market Research Report by Research and Markets 2025-2030 includes a Competitive Analysis of NeuraMetrix, Inc., including significant pharma companies such as Biogen, Roche, and Merck https://finance.yahoo.com/news/digital-neuro-biomarkers-market-research-141000900.html

The market is witnessing significant growth owing to various factors such as increased prevalence of neurological disorders, rising geriatric population globally, advances in technology, demand for personalized medicine, and increased investment in the market by private and public players. Digital N...

10/06/2024

Global Digital Biomarkers Market was valued at US$ 2.03 Bn in 2022 and is forecast to reach a value of US$ 22.28 Bn by 2030 at a CAGR of 34.1% between 2023 and 2030. By WhaTech https://www.whatech.com/og/markets-research/medical/889322-digital-biomarkers-market-2031-vision-key-growth-factors-shaping-the-future-of-business.html

global digital biomarkers market was valued at US$ 2.03 Bn in 2022 and is forecast to reach a value of US$ 22.28 Bn by 2030 at a CAGR of 34.1%...

06/29/2024

Neurological Biomarkers Market Projected To Hit USD 24.83 Billion by 2032, With a CAGR of 13.00% from 2024 - 2032. By WhaTech https://www.whatech.com/og/markets-research/medical/849101-neurological-biomarkers-market-projected-to-hit-usd-24-83-billion-by-2032-with-a-cagr-of-13-00-from-2024-2032

04/29/2024

The U.S. Food and Drug Administration (FDA) announced the availability of revised draft guidance for the industry entitled “Early Alzheimer’s Disease: Developing Drugs for Treatment.” This draft guidance is intended to assist sponsors in the clinical development of drugs to treat the stages of sporadic Alzheimer’s disease (AD) that occur before the onset of overt dementia.

FDA strongly supports and encourages continued research in understanding the role of biomarkers in AD and stresses the potential importance of biomarkers in the successful development of effective treatments appropriate for use in the earliest stages of AD.

Clincal / Medical

04/26/2024

The market is estimated to be valued at USD 8.66 Bn in 2024 and is expected to reach USD 14.91 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.1% from 2024 to 2031. By WhaTech https://www.whatech.com/og/markets-research/medical/812909-understanding-the-dynamics-of-the-neurodiagnostics-market-overall-study-report-2024-2031

04/05/2024

Alzheimer's Prevalence Predicted to Double by 2050. By Medscape Neurology https://www.medscape.com/viewarticle/alzheimers-prevalence-predicted-double-2050-2024a10005o1

The rising prevalence of AD comes at the same time as a growing shortage of neurologists and geriatricians is expected to create "dementia neurology deserts" in some states by 2025.

04/04/2024

NeuraMetrix, Inc.: Transforming Neurological Diagnostics with Innovative Digital Biomarkers. By Healthcare Innovation and Technology Lab https://www.hitlab.org/neurametrix-neurological-diagnostics-innovation/